StreetInsider.com News Articles

Form 8-K Jazz Pharmaceuticals For: Jul 23

Fri, 24 Jul 2026 06:16:00 -0400

si-local-file:///var/storage/secattach/20260724/26810166.html

Form 8-K Jazz Pharmaceuticals For: Jul 23

Fri, 24 Jul 2026 06:16:00 -0400

si-local-file:///var/storage/secattach/20260724/26810166.html

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.

For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.

United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

Mon, 20 Jul 2026 16:15:00 -0400

DUBLIN, July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update.

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

Mon, 20 Jul 2026 16:15:00 -0400

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

Mon, 20 Jul 2026 16:15:00 -0400

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

Mon, 20 Jul 2026 16:15:00 -0400

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.

Canaccord Starts Jazz Pharmaceuticals (JAZZ) at Buy

Thu, 16 Jul 2026 16:07:34 -0400

Canaccord analyst Gary Newman initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and a price target of $290.00.

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $239.32 yesterday.

Form DEFA14A Jazz Pharmaceuticals

Tue, 14 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260714/26768694.html

Form DEFA14A Jazz Pharmaceuticals

Tue, 14 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260714/26768694.html

Jazz Pharmaceuticals (JAZZ) PT Raised to $285 at Wells Fargo

Tue, 14 Jul 2026 06:25:55 -0400

Wells Fargo analyst Mohit Bansal raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $285.00 (from $265.00) while maintaining a Overweight rating.

Jazz Pharmaceuticals (JAZZ) PT Raised to $260 at Barclays

Tue, 14 Jul 2026 05:12:54 -0400

Barclays analyst Etzer Darout raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $260.00 (from $253.00) while maintaining a Overweight rating.

Jazz Pharmaceuticals (JAZZ) PT Lowered to $254 at Truist Securities

Tue, 07 Jul 2026 07:09:21 -0400

Truist Securities analyst Gregory Renza lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $254.00 (from $256.00) while maintaining a Buy rating.

Form 4 Jazz Pharmaceuticals For: Jul 01 Filed by: COZADD BRUCE C

Mon, 06 Jul 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260706/26736968.html

Form 4 Jazz Pharmaceuticals For: Jul 01 Filed by: COZADD BRUCE C

Mon, 06 Jul 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260706/26736968.html

Form 4 Jazz Pharmaceuticals For: Jun 30 Filed by: Pearce Samantha

Thu, 02 Jul 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260702/26729924.html

Form 4 Jazz Pharmaceuticals For: Jun 30 Filed by: Pearce Samantha

Thu, 02 Jul 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260702/26729924.html

Form 4 Jazz Pharmaceuticals For: Jun 30 Filed by: GALA RENEE D

Thu, 02 Jul 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260702/26729902.html